John Hewitt
Internal Medicine · Bakersfield, CANPI 1396833265
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,313 and has fallen 69.4% since, to $402 in 2023. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$859
- Teva Pharmaceuticals USA, Inc.$614
- Lilly USA, LLC$495
- AbbVie$405
- Boehringer Ingelheim$337
- GSK$260
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,402100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $859 |
| Teva Pharmaceuticals USA, Inc. | 47 | $614 |
| Lilly USA, LLC | 27 | $495 |
| AbbVie(2 entities) | 23 | $405 |
| Boehringer Ingelheim | 16 | $337 |
| GSK | 13 | $260 |
| Merck | 11 | $199 |
| Johnson & Johnson | 10 | $185 |
| Novo Nordisk | 9 | $164 |
| Biohaven Pharmaceuticals, Inc. | 6 | $129 |
| Amarin Pharma, Inc. | 7 | $124 |
| Pfizer | 6 | $93 |
| Novartis | 4 | $75 |
| Bayer | 2 | $58 |
| Amgen | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 1 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Almatica Pharma LLC | 1 | $25 |
| Dexcom, Inc. | 1 | $22 |
| Sanofi | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Circassia Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Medicure Pharma Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$125
How this compares
$4,408 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlvescoCiclesonide | 11 | $1,150 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $633 |
| Methylprednisolone | 27 | $259 |
| Doxycycline Hyclate | 24 | $237 |
| Rosuvastatin Calcium | 16 | $201 |
| Prednisone | 17 | $131 |
| Azithromycin | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bakersfield
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.